Update on Juvenile Spondyloarthritis

Rheumatic Disease Clinics of North America

Volumn 39, Issue 4, 2013, Pages 767-788

  Ramanathan, Anusha ^a   Srinivasalu, Hemalatha ^b   Colbert, Robert A ^c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Axial spondyloarthritis; Enthesitis related arthritis; HLA B27; Juvenile psoriatic arthritis; Juvenile spondyloarthritis

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; BACKACHE; CLINICAL FEATURE; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ECHOGRAPHY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IRIDOCYCLITIS; JUVENILE SPONDYLOARTHRITIS; PATHOGENESIS; PERIPHERAL ARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; SACROILIITIS; SPONDYLARTHRITIS; SYMPTOM ASSESSMENT; TREATMENT PLANNING;

AXIAL SPONDYLOARTHRITIS; ENTHESITIS-RELATED ARTHRITIS; HLA-B27; JUVENILE PSORIATIC ARTHRITIS; JUVENILE SPONDYLOARTHRITIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, REACTIVE; CHILD; HUMANS; INFLAMMATORY BOWEL DISEASES; SACROILIITIS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING;

EID: 84886781853     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.06.002     Document Type: Review

References (103)

1. Rosenberg A.M., Petty R.E. Asyndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982, 25:1041-1047.
2. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. JRheumatol 2004, 31:390-392.
3. Colbert R.A. Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond. Nat Rev Rheumatol 2010, 6:477-485.
4. Rudwaleit M., van der Heijde D., Landewe R., et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
5. Rudwaleit M., van der Heijde D., Landewe R., et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31.
6. Dougados M., van der Linden S., Juhlin R., et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991, 34:1218-1227.
7. Amor B., Dougados M., Mijiyawa M. Criteres de classification des spondyloarthropathies. Rev Rhum Mal Osteoartic 1990, 57:85-89.
8. Feldtkeller E., Khan M.A., van der Heijde D., et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23:61-66.
9. Burgos-Vargas R. The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: a critical appraisal for the pediatric rheumatologist. Pediatr Rheumatol Online J 2012, 10:14.
10. Sherry D.D., Sapp L.R. Enthesalgia in childhood: site-specific tenderness in healthy subjects and in patients with seronegative enthesopathic arthropathy. JRheumatol 2003, 30:1335-1340.
11. Weiss P.F. Diagnosis and treatment of enthesitis-related arthritis. Adolesc Health Med Ther 2012, 2012:67-74.
12. Weiss P.F., Beukelman T., Schanberg L.E., et al. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. JRheumatol 2012, 39:2341-2351.
13. Weiss P.F., Klink A.J., Behrens E.M., et al. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken) 2011, 63:1307-1312.
14. Gandjbakhch F., Terslev L., Joshua F., et al. Ultrasound in the evaluation of enthesitis: status and perspectives. Arthritis Res Ther 2011, 13:R188.
15. Jousse-Joulin S., Breton S., Cangemi C., et al. Ultrasonography for detecting enthesitis in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011, 63:849-855.
16. Bandinelli F., Milla M., Genise S., et al. Ultrasound discloses entheseal involvement in inactive and low active inflammatory bowel disease without clinical signs and symptoms of spondyloarthropathy. Rheumatology 2011, 50:1275-1279.
17. Eder L., Barzilai M., Peled N., et al. The use of ultrasound for the assessment of enthesitis in patients with spondyloarthritis. Clin Radiol 2013, 68:219-223.
18. Marchesoni A., De Lucia O., Rotunno L., et al. Entheseal power Doppler ultrasonography: a comparison of psoriatic arthritis and fibromyalgia. JRheumatol Suppl 2012, 89:29-31.
19. Weber U., Pfirrmann C.W., Kissling R.O., et al. Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord 2007, 8:20.
20. Coates L.C., Hodgson R., Conaghan P.G., et al. MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol 2012, 26:805-822.
21. Althoff C.E., Sieper J., Song I.H., et al. Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis 2013, 72(6):967-973.
22. Rachlis A.C., Babyn P.S., Lobo-Mueller E., et al. Whole body magnetic resonance imaging in juvenile spondyloarthritis: will it provide vital information compared to clinical exam alone?. Arthritis Rheum 2011, 63(Suppl 10):749.
23. Srinivasalu H., Hill S.C., Montealegre Sanchez G., et al. Whole body magnetic resonance imaging in evaluation of enthesitis in spondyloarthropathy. Arthritis Rheum 2012, 64(Suppl 10):S848.
24. Gensler L.S., Ward M.M., Reveille J.D., et al. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 2008, 67:233-237.
25. Lin Y.C., Liang T.H., Chen W.S., et al. Differences between juvenile-onset ankylosing spondylitis and adult-onset ankylosing spondylitis. JChin Med Assoc 2009, 72:573-580.
26. Stoll M.L., Bhore R., Dempsey-Robertson M., et al. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. JRheumatol 2010, 37:2402-2408.
27. Alvarez-Madrid C., Merino R., De Inocencio J., et al. Tarsitis as an initial manifestation of juvenile spondyloarthropathy. Clin Exp Rheumatol 2009, 27:691-694.
28. Sieper J., van der Heijde D., Landewe R., et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009, 68:784-788.
29. Pagnini I., Savelli S., Matucci-Cerinic M., et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. JRheumatol 2010, 37:2395-2401.
30. Rudwaleit M., Jurik A.G., Hermann K.G., et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009, 68:1520-1527.
31. Sieper J., Rudwaleit M., Baraliakos X., et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68(Suppl 2):ii1-ii44.
32. Wendling D. Uveitis in seronegative arthritis. Curr Rheumatol Rep 2012, 14:402-408.
33. Chang J.H., McCluskey P.J., Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005, 50:364-388.
34. Cassidy J., Kivlin J., Lindsley C., et al. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006, 117:1843-1845.
35. Jacques P., Van Praet L., Carron P., et al. Pathophysiology and role of the gastrointestinal system in spondyloarthritides. Rheum Dis Clin North Am 2012, 38:569-582.
36. Deepthi R.V., Bhat S.P., Shetty S.M., et al. Juvenile spondyloarthritis with microscopic colitis. Indian Pediatr 2012, 49:579-580.
37. Stoll M.L., Punaro M., Patel A.S. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. JRheumatol 2011, 38:2274-2275.
38. Stoll M.L., Patel A.S., Punaro M., et al. MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. Pediatr Rheumatol Online J 2012, 10:6.
39. Bremander A., Petersson I.F., Bergman S., et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011, 63:550-556.
40. Park S.H., Sohn I.S., Joe B.H., et al. Early cardiac valvular changes in ankylosing spondylitis: a transesophageal echocardiography study. JCardiovasc Ultrasound 2012, 20:30-36.
41. Stamato T., Laxer R.M., de Freitas C., et al. Prevalence of cardiac manifestations of juvenile ankylosing spondylitis. Am J Cardiol 1995, 75:744-746.
42. Stoll M.L., Zurakowski D., Nigrovic L.E., et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006, 54:3564-3572.
43. Stoll M.L., Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol 2011, 23:437-443.
44. Aydin S.Z., Castillo-Gallego C., Ash Z.R., et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology 2012, 225:231-235.
45. Tan A.L., Tanner S.F., Waller M.L., et al. High-resolution [18F]fluoride positron emission tomography of the distal interphalangeal joint in psoriatic arthritis-a bone-enthesis-nail complex. Rheumatology (Oxford) 2013, 52:898-904.
46. McGonagle D.G., Helliwell P., Veale D. Enthesitis in psoriatic disease. Dermatology 2012, 225:100-109.
47. Tan A.L., Benjamin M., Toumi H., et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology 2007, 46:253-256.
48. Reveille J.D. Genetics of spondyloarthritis-beyond the MHC. Nat Rev Rheumatol 2012, 8:296-304.
49. Layh-Schmitt G., Colbert R.A. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol 2008, 20:392-397.
50. Hinks A., Martin P., Flynn E., et al. Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthritis Res Ther 2011, 13:R12.
51. Delay M.L., Turner M.J., Klenk E.I., et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009, 60:2633-2643.
52. Glatigny S., Fert I., Blaton M.A., et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum 2012, 64:110-120.
53. Wendling D., Cedoz J.P., Racadot E., et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007, 74:304-305.
54. Singh R., Aggarwal A., Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. JRheumatol 2007, 34:2285-2290.
55. Utriainen L., Firmin D., Wright P., et al. Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondylarthritis. Arthritis Rheum 2012, 64:3199-3209.
56. Zeng L., Lindstrom M.J., Smith J.A. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum 2011, 63:3807-3817.
57. Bowness P., Ridley A., Shaw J., et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. JImmunol 2011, 186:2672-2680.
58. Burton P.R., Clayton D.G., Cardon L.R., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
59. Evans D.M., Spencer C.C., Pointon J.J., et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011, 43:761-767.
60. Sherlock J.P., Joyce-Shaikh B., Turner S.P., et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012, 18:1069-1076.
61. Zochling J., van der Heijde D., Burgos-Vargas R., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442-452.
62. Jarrett S.J., Sivera F., Cawkwell L.S., et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009, 68:1466-1469.
63. Burgos-Vargas R., Vazquez-Mellado J., Pacheco-Tena C., et al. A26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002, 61:941-942.
64. Huang J.L., Chen L.C. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 1998, 17:359-363.
65. van Rossum M.A., Fiselier T.J., Franssen M.J., et al. Sulfasalazine in the treatment ofjuvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998, 41:808-816.
66. Dougados M., Baeten D. Spondyloarthritis. Lancet 2011, 377:2127-2137.
67. Burgos-Vargas R., Casasola-Vargas J., Gutierrez-Suarez R., et al. Efficacy, safety, and tolerability of infliximab in juvenile-onset spondyloarthropathies (JO-SpA): results of a three-month, randomized, double-blind, placebo-controlled trial phase. Arthritis Rheum 2007, 56:S319.
68. Schmeling H., Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int 2004, 24:173-176.
69. Tse S.M., Burgos-Vargas R., Laxer R.M. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005, 52:2103-2108.
70. Henrickson M., Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. JRheumatol 2004, 31:2055-2061.
71. Horneff G., De Bock F., Foeldvari I., et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009, 68:519-525.
72. Otten M.H., Prince F.H., Armbrust W., et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011, 306:2340-2347.
73. Otten M.H., Prince F.H., Twilt M., et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis-data from the Dutch arthritis and biologicals in children register, 1999-2010. JRheumatol 2011, 38:2258-2263.
74. Horneff G., Fitter S., Foeldvari I., et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012, 14:R230.
75. Beukelman T., Patkar N.M., Saag K.G., et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011, 63:465-482.
76. Guglielmi G., Cascavilla A., Scalzo G., et al. Imaging findings of sacroiliac joints in spondyloarthropathies and other rheumatic conditions. Radiol Med 2011, 116:292-301.
77. Braun J., van den Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
78. Rudwaleit M., Listing J., Brandt J., et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665-670.
79. Davis J.C., Van der Heijde D.M., Dougados M., et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. JRheumatol 2005, 32:1751-1754.
80. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. JRheumatol 2009, 36:801-808.
81. Rudwaleit M., Schwarzlose S., Hilgert E.S., et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67:1276-1281.
82. Maksymowych W.P., Elewaut D., Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012, 64:1713-1719.
83. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52:1756-1765.
84. van der Heijde D., Landewe R., Baraliakos X., et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58:3063-3070.
85. van der Heijde D., Landewe R., Einstein S., et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331.
86. van der Heijde D., Salonen D., Weissman B.N., et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127.
87. Haroon N., Inman R.D., Learch T.J., et al. The impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013, 64. [Epub ahead of print].
88. Sieper J., Kivitz A.J., Van Tubergen A.M., et al. Rapid improvements in patient reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study. Arthritis Rheum 2012, 64(Suppl 10):S558.
89. Landewe R., Rudwaleit M., van der Heijde D., et al. Effect of certolizumab pegol on signs and symptoms of ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24 week results of a double-blind randomized placebo-controlled phase 3 axial spondyloarthritis study. Arthritis Rheum 2012, 64(Suppl 10):S777.
90. Song I.H., Heldmann F., Rudwaleit M., et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62:1290-1297.
91. Bennett A.N., Tan A.L., Coates L.C., et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology 2008, 47:223-224.
92. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70:1108-1110.
93. Lekpa F.K., Farrenq V., Canoui-Poitrine F., et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012, 79:47-50.
94. Sieper J., Porter-Brown B., Thompson L., et al. Assessment of short-term symptomatic efficacy of tocilizumab in anklyosing spondylitis: results of randomized, placebo-controlled trials. Ann Rheum Dis 2013, [Epub ahead of print].
95. Baeten D., et al. The anti-IL-17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2011, 70(Suppl 3):127.
96. Baraliakos X., Braun J., Laurent D.D., et al. Long term inhibition of interleukin (IL)-17A with secukinumab improves clinical symptoms and reduces spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis. Arthritis Rheum 2012, 64(Suppl 10):S574.
97. Pathen E., Abraham S., Van Rossen E., et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2012, [Epub ahead of print].
98. Gladman D.D., Inman R.D., Cook R.J., et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. JRheumatol 2007, 34:1740-1745.
99. Gladman D.D., Cook R.J., Schentag C., et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. JRheumatol 2004, 31:1126-1131.
100. Heuft-Dorenbosch L., Spoorenberg A., van Tubergen A., et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127-132.
101. Mander M., Simpson J.M., McLellan A., et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987, 46:197-202.
102. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with Infliximab-a double-blind placebo controlled multicenter trial. Lancet 2002, 359:1187-1193.
103. Maksymowych W.P., Mallon C., Morrow S., et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009, 68:948-953.